Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of levodopa.

× No keyword cloud information.

65 in total

1. Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors: Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal: Pharm Res Date: 2004-01 Impact factor: 4.200

2. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors: H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal: J Neurol Neurosurg Psychiatry Date: 1997-10 Impact factor: 10.154

Review 3. [Present status and future possibilities of adjuvant pharmacotherapy for aphasia].

Authors: C Korsukewitz; C Breitenstein; M Schomacher; S Knecht
Journal: Nervenarzt Date: 2006-04 Impact factor: 1.214

4. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors: Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal: J Pharmacokinet Pharmacodyn Date: 2005-08 Impact factor: 2.745

Review 5. Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors: Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal: Drugs Aging Date: 2019-06 Impact factor: 3.923

6. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors: M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal: J Neural Transm (Vienna) Date: 1997 Impact factor: 3.575

7. In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study.

Authors: D Deleu; S Sarre; G Ebinger; Y Michotte
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1991-11 Impact factor: 3.000

8. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.

Authors: Pedro Silveira; Manuel Vaz-da-Silva; Luis Almeida; Joana Maia; Amilcar Falcão; Ana Loureiro; Leonel Torrão; Rita Machado; Lyndon Wright; Patrício Soares-da-Silva
Journal: Eur J Clin Pharmacol Date: 2003-09-27 Impact factor: 2.953

9. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Authors: Dag Nyholm; Per Odin; Anders Johansson; Krai Chatamra; Charles Locke; Sandeep Dutta; Ahmed A Othman
Journal: AAPS J Date: 2012-12-11 Impact factor: 4.009

Review 10. Anti-parkinsonian drugs today.

Authors: N P Quinn
Journal: Drugs Date: 1984-09 Impact factor: 9.546